Osteo Signal to be Integrated into Siemens Healthineers Research Platforms, Marking a New Step Toward Global Collaboration

At the Siemens Healthineers Shanghai Innovation Center, PROMEDIUS CEO Hyunjin Bae (left) and Dr. Lei Wang (right), Vice President of Digital & Automation at Siemens Healthineers Shanghai Medical Equipment Co., Ltd., signed the contract.

PROMEDIUS, an AI company focused on aging and metabolic diseases, announced that it has signed an AI integration agreement with Siemens Healthineers China on September 18, 2025.

Under this agreement, PROMEDIUS’ Chest X-ray–based Osteoporosis Screening AI Solution, Osteo Signal, will be integrated into Siemens Healthineers’ Research Platforms, including the AI-Rad Companion Research Frontier and syngo.via Frontier Research Platform.

Through Siemens Healthineers’ Research Platforms, Osteo Signal will become accessible to hospital research partners and clinical teams in China. PROMEDIUS plans to enhance product performance by leveraging real-world research data and user feedback, ultimately demonstrating the clinical value of Osteo Signal and strengthening its global collaboration with Siemens Healthineers.

Hyunjin Bae, CEO of PROMEDIUS, stated: “This agreement marks the first step in building an AI-driven preventive healthcare ecosystem that brings together Siemens Healthineers’ global infrastructure and PROMEDIUS’ AI technology,” he said. “We will continue to advance the performance of Osteo Signal and expand into global markets as we pursue our mission of Healthy Aging through AI.”